Patient Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$80M |
| 2 |
Expedia Group
EXPE
|
+$76.1M |
| 3 |
OneMain Financial
OMF
|
+$73.1M |
| 4 |
Citigroup
C
|
+$63.6M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$63.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
QUOT
Quotient Technology Inc
QUOT
|
+$2.69M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$2.59M |
| 3 |
ADT
ADT
|
+$1.39M |
| 4 |
Rocket Companies
RKT
|
+$131K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 34.24% |
| 2 | Financials | 22.56% |
| 3 | Industrials | 10.69% |
| 4 | Communication Services | 10.27% |
| 5 | Energy | 9.14% |
Similar funds
Patient Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Patient Capital Management held 45 positions worth $1.8B, up 701% from $224M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Patient Capital Management deployed $1.41B of net new capital in Q2 2023, opening 4 new positions and adding to 33 existing holdings. Its largest new stake was People Inc: 834,615 shares worth $43M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 34% of assets, down from 35% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $2.59M trimmed.
- Patient Capital Management's largest Q2 2023 buy was People Inc: 834,615 shares worth $43M.
- Patient Capital Management added most to Amazon in Q2 2023, an estimated $80M increase.
- Patient Capital Management's biggest Q2 2023 reduction was Teva Pharmaceuticals, cutting an estimated $2.59M.
- Patient Capital Management fully exited Quotient Technology Inc in Q2 2023, selling an estimated $2.69M.
- Patient Capital Management's ten largest holdings make up 45% of its $1.8B portfolio in Q2 2023.
- Patient Capital Management opened 4 new positions and closed 1 in Q2 2023.
- Patient Capital Management's portfolio value rose 701% quarter-over-quarter to $1.8B.
Based on Patient Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.